Does the alignment of a replacement artificial heart valve in the same direction as the patient’s own heart valve affect outcomes in aortic valve implantation? A feasibility study

ISRCTN ISRCTN16090439
DOI https://doi.org/10.1186/ISRCTN16090439
IRAS number 309300
Secondary identifying numbers IRAS 309300
Submission date
07/03/2023
Registration date
20/04/2023
Last edited
17/01/2025
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Aortic valve stenosis is a type of heart valve disease in which the valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. If symptoms become severe it will probably need surgery to replace the valve. A minimally invasive way of replacing a heart valve is through what is known as a transcatheter aortic valve implantation (TAVI) procedure. Currently, during a TAVI procedure, the new valve is not placed in the exact orientation of the old valve because it is not sure if this is possible. Part of this study is to try and see if the new valve can be put in the exact position of the old valve and if this will have an effect on how the valve functions. It is also postulated that orientating the valve in this way will make it easier to access the heart arteries if it is needed in future for any reason.

Who can participate?
Patients with severe aortic stenosis undergoing TAVI as decided by a structural heart multi-disciplinary team, who are aged between 70 and 100 years old and are considered clinically able to undergo all the procedures necessary for the intervention.

What does the study involve?
Patients referred for either outpatient or inpatient TAVI will be approached in the first instance by their clinical team. If the patient agrees to be approached by the research team, then this will take place. If informed consent is provided by the patient they will attend the TAVI procedure in the normal way. During the procedure, the replacement heart valve will be orientated in the same way as the patient’s own aortic valve. At the end of the TAVI, access to the heart arteries will be checked by catheters which are routinely used for heart artery angiograms and no dye will be injected. Overall the procedure should take no more than 10 minutes more than a standard TAVI procedure. A month later a return visit and CT scan checking the heart and arteries, will take place and this visit will take approximately 30 minutes.

What are the possible benefits and risks of participating?
It is unknown whether there will be an immediate benefit of taking part in the study beyond that expected from having your aortic valve replaced. However, the results of this study may benefit future patients having TAVI as it could improve our technique and knowledge of this procedure. There is a benefit of having the heart arteries assessed which may influence the patient’s treatment. It is not believed that there are additional risks of taking part in the study over and above those involved with a standard TAVI procedure. However, there will be a CT scan after the TAVI which is one more scan than if not taking part.

Where is the study run from?
The Royal Sussex County Hospital Brighton (UK)

When is the study starting and how long is it expected to run for?
March 2022 to September 2023

Who is funding the study?
Terumo UK Ltd (UK)

Who is the main contact?
Dr Christopher Pavitt, christopher.pavitt@nhs.net (UK)

Contact information

Dr Christopher Pavitt
Principal Investigator

Clinical Research Facility
2nd Floor Sussex House
1 Abbey Road
Brighton
BN2 1ES
United Kingdom

ORCiD logoORCID ID 0000-0001-5067-8248
Phone +44 (0)1273 696955
Email christopher.pavitt@nhs.net
Dr Christopher Pavitt
Scientific

Clinical Research Facility
2nd Floor Sussex House
1 Abbey Road
Brighton
BN2 1ES
United Kingdom

Phone +44 (0)1273 696955
Email christopher.pavitt@nhs.net
Mr Duncan Fatz
Public

Clinical Research Facility
2nd Floor Sussex House
1 Abbey Road
Brighton
BN2 1ES
United Kingdom

Phone +44 (0)1273 696955
Email duncan.fatz@nhs.net

Study information

Study designInterventional feasibility study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typePrevention
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleTechnical feasibility of neo-commissural alignment in Transcatheter Aortic Valve Implantation (TAVI): an exploratory study in patients undergoing TAVI describing procedural outcomes and effect on coronary artery access
Study acronymNeoTAVI
Study objectivesThe study investigates whether aligning a replacement heart valve (TAVI) in the same orientation as the patient's own heart valve is feasible and facilitates access to coronary arteries.
Ethics approval(s)Approved 11/05/2022, London - Surrey Borders Research Ethics Committee (Held remotely via Teleconference/ZOOM; +44 (0)207 104 8057, (0)207 104 8104, (0)207 104 8199; surreyborders.rec@hra.nhs.uk), ref: 22/PR/0394
Health condition(s) or problem(s) studiedAortic stenosis
InterventionTraditionally aortic valve replacement for patients with severe symptomatic aortic stenosis was achieved with surgical removal and implantation of a new mechanical or tissue valve necessitating cardiopulmonary bypass. Transcatheter aortic valve implantation (TAVI) or ‘key-hole’ surgery of the heart in a surgical setting has become the standard of care in replacing a diseased aortic valve in patients deemed a high or medium risk for conventional open surgical replacement, and recent data and guideline recommendations have extended its use to all surgical risk groups. Pre-procedural planning is of paramount importance and computer tomography (CT) has become the imaging modality of choice due to its high temporal and spatial resolution, and its ability to accurately delineate vascular structures. In this regard, the optimum vascular access route can be identified, and CT allows the operator to reliably measure the aortic root and size the TAVI valve accordingly. Evidence has shown that the use of CT has reduced procedural complication rates, such as aortic rupture, valve embolization and post-implant para-valvular leak.

Current practice is to implant the TAVI valve at a pre-determined depth, but unlike in surgical aortic valve replacement (AVR) in which the valve commissures are aligned to the native valve, the orientation and alignment of the TAVI valve is not routinely taken into consideration or deemed clinically necessary. There is growing evidence that achieving neo-commissural alignment with TAVI may improve valve haemodynamics and reduce valve hypo-attenuated leaflet thrombosis (HALT), both of which may impact valve function. Furthermore, it may improve coronary access in patients requiring coronary artery intubation and facilitate repeat TAVI. Coronary access post-TAVI is attracting attention and is of particular importance as the number of TAVI implants grows and extends to younger patients who are more likely to require coronary intervention after valve replacement.

This single-arm, non-randomised study involves TAVI. Patients will be recruited for the study through the normal waiting list for aortic valve implantation at the University Hospitals Sussex NHS Foundation Trust. The team conducting the TAVI procedure are professors, consultants or specialised registrars in cardiology and electrophysiology. They are all registered with the GMC and have current Good Clinical Practice certification as well as training conforming to all the relevant standard operating procedures of the University Hospitals Sussex NHS Foundation Trust.
Intervention typeProcedure/Surgery
Primary outcome measure1. TAVI valve alignment compared to patient's own aortic valve measured using cardiac-CT focusing on calculating the optimum commissural alignment during surgery
2. Coronary access using standard diagnostic catheters measured using CT-fractional flow reserve before and after the TAVI procedure
Secondary outcome measuresComputational fluid dynamics assessment of aortic blood flow measured using CT-fractional flow reserve before and after the TAVI procedure
Overall study start date07/03/2022
Completion date22/09/2023

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit70 Years
Upper age limit100 Years
SexBoth
Target number of participants30
Total final enrolment30
Key inclusion criteriaPatients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) as decided by the structural heart multi-disciplinary team (MDT)
Key exclusion criteria1. Lack of vascular access to permit TAVI
2. Transaxillary or transcaval vascular access
3. Patient unable to undergo required post-TAVI CT-scan
4. Patient unable to give informed consent
5. Aged <70 or >100 years old
6. Decreased renal function eGFR <30ml/min
7. Pregnancy
Date of first enrolment07/07/2022
Date of final enrolment07/09/2023

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Royal Sussex County Hospital
Eastern Road
Brighton
BN2 5BE
United Kingdom

Sponsor information

University Hospitals Sussex NHS Foundation Trust
Hospital/treatment centre

Clinical Research Facility
2nd Floor Sussex House
1 Abbey Road
Brighton
BN2 1ES
England
United Kingdom

Phone +44 (0)1273696955
Email scott.harfield@nhs.net
Website https://www.uhsussex.nhs.uk/
ROR logo "ROR" https://ror.org/03wvsyq85

Funders

Funder type

Industry

Terumo UK Ltd

No information available

Results and Publications

Intention to publish date07/10/2024
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe current data sharing plans for this study are unknown and will be available at a later date.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
HRA research summary 28/06/2023 No No
Other unpublished results 17/01/2025 No No

Additional files

ISRCTN16090439 NeoTAVI Report to ISRCTN.pdf

Editorial Notes

17/01/2025: A file of unpublished results was uploaded as an additional file.
23/10/2024: The following changes were made to the trial record:
1. The overall end date was changed from 07/07/2024 to 22/09/2023.
2. The total final enrolment was added.
15/09/2023: The following changes were made to the study record:
1. The overall study end date was changed from 07/10/2023 to 07/07/2024.
2. The intention to publish date was changed from 07/10/2024 to 07/10/2024.
14/03/2023: Trial's existence confirmed by HRA and Health and Care Research Wales (HCRW).